Syncom Formulations MD, Vijay Shankarlal Bankda, Resigns Effective August 11, 2026
Mr. Vijay Shankarlal Bankda has resigned as Managing Director of Syncom Formulations (India) Limited. His resignation is effective August 11, 2026. The company received the resignation on August 8, 2026. This disclosure follows SEBI regulations.
The resignation of a Managing Director can impact company leadership and strategic direction, warranting a medium impact assessment.
The resignation of a Managing Director is a significant event but does not inherently carry positive or negative financial implications without further context on the reasons or the successor.
Syncom Formulations (India) Limited has announced the resignation of its Managing Director, Mr. Vijay Shankarlal Bankda (DIN: 00023027). His resignation is effective from August 11, 2026. The company received his resignation letter on August 8, 2026, at 2:35 PM. The announcement complies with Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, and relevant SEBI Master Circulars. Detailed disclosures regarding the change in directorship and management, including the reason for resignation and cessation date, are provided as per regulatory requirements. No relationship between directors is disclosed, and a brief profile is marked as not applicable.
What to do with a filing like this
Syncom Formulations (India) Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Syncom Formulations (India) Limited. Read the original for the full detail.